Klaria Pharma Holding AB Total Liabilities
Klaria Pharma Holding AB total liabilities. Based on the latest financial reports, Klaria Pharma Holding AB (KLAR) has total liabilities worth Skr50.62 Million SEK (≈ $5.45 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check KLAR cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Klaria Pharma Holding AB (2014–2025)
Total liabilities of Klaria Pharma Holding AB from 2014 to 2025. This chart illustrates how Klaria Pharma Holding AB's total liabilities have evolved over time, based on quarterly financial data.
Klaria Pharma Holding AB Competitors by Total Liabilities
The table below lists competitors of Klaria Pharma Holding AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
B.V. Delftsch Aardewerkfabriek "De Porceleyne Fles Anno 1653"
AS:PORF
|
Netherlands | €28.16 Million |
|
Tempo Inti Media Tbk
JK:TMPO
|
Indonesia | Rp206.41 Billion |
|
Alps Industries Limited
NSE:ALPSINDUS
|
India | Rs112.92 Million |
|
Stingray Group Inc
TO:RAY-B
|
Canada | CA$866.47 Million |
|
Compass Gold Corp
V:CVB
|
Canada | CA$1.82 Million |
|
Aegis Brands Inc
TO:AEG
|
Canada | CA$31.73 Million |
|
TG Metals Ltd
AU:TG6
|
Australia | AU$1.42 Million |
|
S-Fuelcell co. Ltd
KQ:288620
|
Korea | ₩39.24 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Klaria Pharma Holding AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see KLAR total assets.
Liquidity & Leverage Metrics
Klaria Pharma Holding AB Total Liabilities Ratios Explained
Klaria Pharma Holding AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Klaria Pharma Holding AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Klaria Pharma Holding AB (2014–2025)
The table below shows the annual total liabilities of Klaria Pharma Holding AB from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr44.65 Million ≈ $4.80 Million |
-17.26% |
| 2024-12-31 | Skr53.96 Million ≈ $5.81 Million |
+69.62% |
| 2023-12-31 | Skr31.81 Million ≈ $3.42 Million |
-28.01% |
| 2022-12-31 | Skr44.19 Million ≈ $4.76 Million |
-9.62% |
| 2021-12-31 | Skr48.89 Million ≈ $5.26 Million |
+114.33% |
| 2020-12-31 | Skr22.81 Million ≈ $2.45 Million |
+16.29% |
| 2019-12-31 | Skr19.62 Million ≈ $2.11 Million |
+69.77% |
| 2018-12-31 | Skr11.55 Million ≈ $1.24 Million |
+391.91% |
| 2017-12-31 | Skr2.35 Million ≈ $252.79K |
+17.80% |
| 2016-12-31 | Skr1.99 Million ≈ $214.59K |
-13.04% |
| 2015-12-31 | Skr2.29 Million ≈ $246.76K |
+356.14% |
| 2014-12-31 | Skr502.69K ≈ $54.10K |
-- |
About Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. T… Read more